Table 1 Baseline characteristics of patients and controls.
Characteristic | Intended HSCT cohort (n = 40)a | Controls (n = 20)a | |
|---|---|---|---|
Age | Median (range) | 40.5 (20–70) | 38.5 (21–73) |
Mean | 41.3 | 39.3 | |
Sex | Male | 21 (52.5%) | 9/20 (45.0%) |
Female | 19 (47.5%) | 11/20 (55.0%) | |
Primary diagnosis | AA | 8 (20%) | |
ALL | 9 (22.5%) | ||
AML | 7 (17.5%) | ||
APL | 1 (2.5%) | ||
CGD | 1 (2.5%) | ||
CLL | 1 (2.5%) | ||
Cutaneous Lymphoma | 1 (2.5%) | ||
Follicular Lymphoma | 1 (2.5%) | ||
HL | 1 (2.5%) | ||
Mantle Cell Lymphoma | 1 (2.5%) | ||
MDS | 4 (10.0%) | ||
MM | 1 (2.5%) | ||
Plasmocytic dendritic cell neoplasm | 1 (2.5%) | ||
SCA | 3 (7.5%) | ||
Type of transplant (n = 36)b | HLA matched | 32 (88.8%) | |
Unmatched | 4 (11.1%) | ||
Total Body Irradiation | Yes | 25 (69.4%) | |
Low-dose (<600 Gy) | 6/25 (24.0%) | ||
High-dose (≥600 Gy) | 19/25 (76.0%) | ||
No | 11 (30.5%) | ||
Conditioning regimen | Myeloablative | 20 (55.5%) | |
Non-Myeloablative | 16 (44.4%) | ||
SteM cell source | Cord blood and peripheral blood | 4 (11.1%) | |
Peripheral blood | 32 (88.8%) |
